Vancouver, British Columbia–(Newsfile Corp. – February 23, 2021) – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), is very pleased to announce the appointment of Dr. Linnéa Olofsson as an advisor and consultant for the Company.
Dr. Olofsson will be working with our team in implementing our strategies for the commercialization of our products. With her scientific background and ability to understand the needs in the medical field, she will be collaborating to bring important solutions to meet our goals and objectives.
After receiving her Doctorate in Biophysics in 2014, Dr. Olofsson acquired an extensive Knowledge of Oncology, Immunology, Molecular Biology, Cell Biology, Flow Cytometry, CRISPR/Cas9 gene editing, structure-based drug design (Structure-Activity Relationship) as a post-doctoral researcher for four years. Dr. Olofsson then moved to the private sector as a Field Application Scientist for U.S. – Oxford Nanoimaging. She worked in conjunction with the sales team to identify and qualify sales leads through technical discussions and collaboration. Her contribution to execute strategic marketing plans increased U.S. sales from $3.2 million in 2018 to $6.7 million in 2019. From this, she gained the insight to found ILC Scientific Consulting in Montreal, Quebec, to further use her capabilities in science and business, representing PicoQuant Photonics North America as a sales and application specialist.
Stephen Van Deventer, PreveCeutical’s Chief Executive Officer, commented, “With the Company actively working on development, clinical trials, and commercialization of its products, Dr. Olofsson’s background in academia, as well as the private sector, will be an incredible asset to our team. A skilled scientist with the ability to convey science to businesspeople in terms they can understand. We are very excited and fortunate to have her work with us.”
Dr. Linnéa Olofsson commented, “I’m beyond thrilled and honoured for this opportunity to join PreveCeutical as an advisor. I’ve already had a chance to get familiarized with the pipeline and dig into some of the outstanding research that has been done to date – I see a huge potential for this company in the years to come to provide patients with possibly life-changing solutions to their medical conditions and ailments.”
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.
With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations [email protected]
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical’s anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “will”, “pro forma”, “plans”, “expects”, “may”, “should”, “budget”, “schedules”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical’s research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities.
Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical’s filings are available at www.sedar.com. Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/75178